Cell Robotics begins clinicals of laser skin perforator for blood sampling.
This article was originally published in The Gray Sheet
CELL ROBOTICS BEGINS CLINICALS ON LASER SKIN PERFORATOR following FDA approval of an investigational device exemption for the study July 25. The single-site trial at University of New Mexico Medical School in Albuquerque will compare use of the laser to conventional stainless steel lancets for collecting capillary blood samples, and focus on any changes in blood chemistry from device use. Cell Robotics, Inc. expects to complete the study in four to six weeks.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.